Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET
- PMID: 31308648
- PMCID: PMC6616193
- DOI: 10.2147/COPD.S201899
Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET
Abstract
Background: In light of overall increasing healthcare expenditures, it is mandatory to study determinants of future costs in chronic diseases. This study reports the first longitudinal results on healthcare utilization and associated costs from the German chronic obstructive pulmonary disease (COPD) cohort COSYCONET.
Material and methods: Based on self-reported data of 1904 patients with COPD who attended the baseline and 18-month follow-up visits, direct costs were calculated for the 12 months preceding both examinations. Direct costs at follow-up were regressed on baseline disease severity and other co-variables to identify determinants of future costs. Change score models were developed to identify predictors of cost increases over 18 months. As possible predictors, models included GOLD grade, age, sex, education, smoking status, body mass index, comorbidity, years since COPD diagnosis, presence of symptoms, and exacerbation history.
Results: Inflation-adjusted mean annual direct costs increased by 5% (n.s., €6,739 to €7,091) between the two visits. Annual future costs were significantly higher in baseline GOLD grades 2, 3, and 4 (factors 1.24, 95%-confidence interval [1.07-1.43], 1.27 [1.09-1.48], 1.57 [1.27-1.93]). A history of moderate or severe exacerbations within 12 months, a comorbidity count >3, and the presence of dyspnea and underweight were significant predictors of cost increase (estimates ranging between + €887 and + €3,679, all p<0.05).
Conclusions: Higher GOLD grade, comorbidity burden, dyspnea and moderate or severe exacerbations were determinants of elevated future costs and cost increases in COPD. In addition we identified underweight as independent risk factor for an increase in direct healthcare costs over time.
Keywords: change score; direct costs; healthcare expenditures; inpatient costs; outpatient costs; population-based.
Conflict of interest statement
Johanna I Lutter reports grants from German Federal Ministry of Education and Research during the conduct of the study. Stefan Karrasch reports grants from German Federal Ministry of Education and Research (BMBF) during the conduct of the study. Holger Schulz report grants from German Federal Ministry of Education and Research (BMBF), during the conduct of the study. Claus Vogelmeier report grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, grants from Bayer Schering Pharma AG, grants from MSD, and grants from Pfizer outside the submitted work. Rolf Holle report grants from German Federal Ministry of Education and Research, during the conduct of the study. The authors report no other conflicts of interest in this work.
Similar articles
-
The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29270005 Free PMC article.
-
Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study.Respir Med. 2016 Feb;111:39-46. doi: 10.1016/j.rmed.2015.12.001. Epub 2015 Dec 10. Respir Med. 2016. PMID: 26725462
-
Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.Int J Chron Obstruct Pulmon Dis. 2017 Jul 4;12:1947-1959. doi: 10.2147/COPD.S134618. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28740375 Free PMC article.
-
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:439-460. doi: 10.2147/COPD.S234942. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32161455 Free PMC article.
-
Impact of the financial crisis on COPD burden: Greece as a case study.Eur Respir Rev. 2018 Jan 24;27(147):170106. doi: 10.1183/16000617.0106-2017. Print 2018 Mar 31. Eur Respir Rev. 2018. PMID: 29367410 Free PMC article. Review.
Cited by
-
Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort - Determinants and Consequences.Int J Chron Obstruct Pulmon Dis. 2021 Apr 14;16:987-998. doi: 10.2147/COPD.S304532. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33883892 Free PMC article.
-
Insomnia in chronic obstructive pulmonary disease and associations with healthcare utilization and costs.Respir Res. 2023 Mar 25;24(1):93. doi: 10.1186/s12931-023-02401-w. Respir Res. 2023. PMID: 36964552 Free PMC article.
-
Reliability, Validity, and Responsiveness of the DEG, a Three-Item Dyspnea Measure.J Gen Intern Med. 2022 Aug;37(10):2541-2547. doi: 10.1007/s11606-021-07307-1. Epub 2022 Jan 3. J Gen Intern Med. 2022. PMID: 34981344 Free PMC article. Clinical Trial.
-
Machine learning approaches for practical predicting outpatient near-future AECOPD based on nationwide electronic medical records.iScience. 2024 Mar 20;27(4):109542. doi: 10.1016/j.isci.2024.109542. eCollection 2024 Apr 19. iScience. 2024. PMID: 38577104 Free PMC article.
-
Muscle mass and function are related to respiratory function in chronic obstructive pulmonary disease.Med J Islam Repub Iran. 2021 Mar 13;35:34. doi: 10.47176/mjiri.35.34. eCollection 2021. Med J Islam Repub Iran. 2021. PMID: 34211936 Free PMC article.
References
-
- Geldmacher H, Biller H, Herbst A, et al. [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr. 2008;133(50):2609–2614. - PubMed
-
- Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30234-5 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous